A US adcom will next month try to unravel confusion about PD-L1 status in first-line gastric cancer.

Bicara and DualityBio will soon test market appetite for new oncology issues.

Pfizer’s LILRB1 x LILRB2 bispecific is about to enter the clinic.

Darzalex added another string to its bow, while Kisqali’s early use has been delayed.

Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.

HanchorBio’s HCB301 is among the latest industry projects beginning first-in-human trials.

Earnings season begins again, while big readouts loom for ALX and Fibrogen.

One of the German group’s biggest cancer hopes has fallen flat, raising more questions about targeting an apoptosis pathway.

NX-5948 and BGB-16673 yield data in more CLL patients, but Nurix investors seem unimpressed.